Sign In
Buy OCGN
$1.21
-0.0100 (-0.82%)
At Close: Jun 12, 2026
Ocugen Provides Business Update with Third Quarter 2025 Financial Results
06:30am, Wednesday, 05'th Nov 2025
Phase 2/3 OCU410ST GARDian3 pivotal confirmatory trial is progressing toward 1H 2027 Biologics License Application (BLA) filing with 50% enrollment completed to date European Medicines Agency (EMA) pr
Ocugen to Host Webcast on Wednesday, November 5 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2025 Financial Results
07:30am, Thursday, 23'rd Oct 2025
MALVERN, Pa., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today annou
Ocugen (NASDAQ:OCGN) Trading Up 1.3% – Still a Buy?
02:18am, Tuesday, 21'st Oct 2025
Ocugen, Inc. (NASDAQ: OCGN - Get Free Report) was up 1.3% during trading on Monday. The company traded as high as $1.65 and last traded at $1.62. Approximately 2,521,470 shares traded hands during mid
Ocugen: A Retinal Disease Juggernaut In The Making
11:11am, Tuesday, 23'rd Sep 2025
Ocugen (OCGN) is a clinical-stage biotech focused on modifier gene therapies for inherited retinal diseases, with key catalysts expected by 2026. OCGN's pipeline includes OCU400 (RP/LCA), OCU410ST (St
Why Ocugen Stock Zoomed 12% Higher Today
07:04pm, Monday, 15'th Sep 2025
On Monday, investors clearly saw excellent value in the stock of Ocugen (OCGN 12.15%), a biotech that concentrates on treatments for eye disorders. They traded the company's shares up by more than 12%
Ocugen Shares Are Trading Higher Monday: What's Going On?
04:29pm, Monday, 15'th Sep 2025
Ocugen, Inc. OCGN shares traded higher on Monday after the company announced a licensing agreement with Kwangdong Pharmaceutical for the exclusive Korean rights to OCU400.
MALVERN, Pa., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today exec
Ocugen to Participate in H.C. Wainwright 27th Annual Global Investment Conference & Biotech on Tap 2025
07:02am, Tuesday, 02'nd Sep 2025
MALVERN, Pa., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today anno
Ocugen (OCGN) Upgraded to Buy: Here's What You Should Know
01:01pm, Tuesday, 26'th Aug 2025
Ocugen (OCGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
MALVERN, Pa., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that th
Ocugen, Inc. Announces Closing of $20 Million Registered Direct Offering of Common Stock and Warrants
03:45pm, Tuesday, 12'th Aug 2025
MALVERN, Pa., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the clo
Ocugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and Warrants
05:03pm, Friday, 08'th Aug 2025
MALVERN, Pa., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it
Ocugen (OCGN) Q2 Revenue Jumps 20%
07:16pm, Friday, 01'st Aug 2025
Ocugen (OCGN) Q2 Revenue Jumps 20%
Ocugen, Inc. (OCGN) Q2 2025 Earnings Call Transcript
12:30pm, Friday, 01'st Aug 2025
Ocugen, Inc. (NASDAQ:OCGN ) Q2 2025 Earnings Conference Call August 1, 2025 8:30 AM ET Company Participants Arun Upadhyay - Chief Scientific Officer and Head of Research & Development Huma Qamar - Chi
Ocugen (OCGN) Reports Q2 Loss, Misses Revenue Estimates
10:35am, Friday, 01'st Aug 2025
Ocugen (OCGN) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to a loss of $0.04 per share a year ago.
